JP2022153399A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022153399A5 JP2022153399A5 JP2022107704A JP2022107704A JP2022153399A5 JP 2022153399 A5 JP2022153399 A5 JP 2022153399A5 JP 2022107704 A JP2022107704 A JP 2022107704A JP 2022107704 A JP2022107704 A JP 2022107704A JP 2022153399 A5 JP2022153399 A5 JP 2022153399A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- amino acid
- tcr
- acid residues
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201606172 | 2016-04-08 | ||
| GB1606172.3 | 2016-04-08 | ||
| PCT/EP2017/058576 WO2017174822A1 (en) | 2016-04-08 | 2017-04-10 | T cell receptors |
| JP2018552696A JP7179616B2 (ja) | 2016-04-08 | 2017-04-10 | Ｔ細胞受容体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018552696A Division JP7179616B2 (ja) | 2016-04-08 | 2017-04-10 | Ｔ細胞受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022153399A JP2022153399A (ja) | 2022-10-12 |
| JP2022153399A5 true JP2022153399A5 (https=) | 2023-04-11 |
| JP7437452B2 JP7437452B2 (ja) | 2024-02-22 |
Family
ID=58701591
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018552696A Active JP7179616B2 (ja) | 2016-04-08 | 2017-04-10 | Ｔ細胞受容体 |
| JP2022107704A Active JP7437452B2 (ja) | 2016-04-08 | 2022-07-04 | Ｔ細胞受容体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018552696A Active JP7179616B2 (ja) | 2016-04-08 | 2017-04-10 | Ｔ細胞受容体 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20190135892A1 (https=) |
| EP (2) | EP3440102B1 (https=) |
| JP (2) | JP7179616B2 (https=) |
| KR (1) | KR20190059874A (https=) |
| CN (2) | CN117603339A (https=) |
| AU (2) | AU2017248120B2 (https=) |
| BR (1) | BR112018070600A2 (https=) |
| CA (1) | CA3020530A1 (https=) |
| DK (1) | DK3440102T3 (https=) |
| ES (1) | ES2991142T3 (https=) |
| IL (1) | IL262146A (https=) |
| MX (1) | MX2018012265A (https=) |
| RU (1) | RU2018138836A (https=) |
| SG (1) | SG11201808709VA (https=) |
| WO (1) | WO2017174822A1 (https=) |
| ZA (1) | ZA201806865B (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| MA49156A (fr) | 2014-12-23 | 2020-03-25 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers |
| KR20190059874A (ko) | 2016-04-08 | 2019-05-31 | 어댑티뮨 리미티드 | T 세포 수용체 |
| DK3440106T3 (da) | 2016-04-08 | 2021-10-04 | Adaptimmune Ltd | T-cellereceptorer |
| BR112018070637A2 (pt) * | 2016-04-08 | 2019-02-05 | Adaptimmune Ltd | receptores de células t |
| WO2019069125A1 (en) | 2017-10-06 | 2019-04-11 | Oslo Universitetssykehus Hf | CHIMERIC ANTIGEN RECEPTORS |
| WO2019133443A1 (en) * | 2017-12-28 | 2019-07-04 | Janux Therapeutics, Inc. | Modified t cell receptors |
| WO2019204683A1 (en) | 2018-04-19 | 2019-10-24 | Board Of Regents, The University Of Texas System | T cell receptors with mage-b2 specificity and uses thereof |
| DE102018122546B3 (de) | 2018-09-14 | 2019-12-05 | Immatics Biotechnologies Gmbh | Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden |
| MA53599A (fr) * | 2018-09-14 | 2021-07-21 | Immatics Biotechnologies Gmbh | Procédé de criblage par affinité peptide-cmh à haut débit destiné à des ligands de tcr |
| GB201819540D0 (en) | 2018-11-30 | 2019-01-16 | Adaptimmune Ltd | T cell modification |
| USD998170S1 (en) * | 2019-04-10 | 2023-09-05 | Inveox Gmbh | Sample container |
| CN110172091B (zh) * | 2019-04-28 | 2020-04-03 | 天津亨佳生物科技发展有限公司 | 一种针对egfr l858r基因突变的特异性t细胞受体及其应用 |
| WO2020263830A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
| AU2020327671A1 (en) | 2019-08-13 | 2022-03-03 | King's College London | Immunoresponsive cells armoured with spatiotemporally restricted activity of cytokines of the IL-1 superfamily |
| TWI890283B (zh) | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| US20230190803A1 (en) * | 2020-05-13 | 2023-06-22 | Adaptimmune Limited | Method of treatment of cancer or tumour |
| CA3183756A1 (en) | 2020-05-19 | 2021-11-25 | Amgen Inc. | Mageb2 binding constructs |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| AU2021410689A1 (en) * | 2020-12-22 | 2023-07-06 | Amgen Inc. | Mage-b2-specific t-cell receptors |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| AU2022375782B2 (en) | 2021-10-28 | 2026-02-26 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| JP7787991B2 (ja) | 2021-10-29 | 2025-12-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
| KR20240123836A (ko) | 2021-12-22 | 2024-08-14 | 길리애드 사이언시즈, 인코포레이티드 | 이카로스 아연 핑거 패밀리 분해제 및 이의 용도 |
| US12122764B2 (en) | 2021-12-22 | 2024-10-22 | Gilead Sciences, Inc. | IKAROS zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CR20240451A (es) | 2022-04-21 | 2024-12-04 | Gilead Sciences Inc | Compuestos de modulación de kras g12d |
| KR20250028371A (ko) | 2022-07-01 | 2025-02-28 | 길리애드 사이언시즈, 인코포레이티드 | Cd73 화합물 |
| AU2023409398A1 (en) | 2022-12-22 | 2025-06-05 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| AU2024252725A1 (en) | 2023-04-11 | 2025-11-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| CR20250446A (es) | 2023-04-21 | 2025-12-02 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| AU2024306338A1 (en) | 2023-06-30 | 2026-01-08 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN121620513A (zh) | 2023-07-26 | 2026-03-06 | 吉利德科学公司 | Parp7抑制剂 |
| KR20260046403A (ko) | 2023-07-26 | 2026-04-07 | 길리애드 사이언시즈, 인코포레이티드 | Parp7 저해제 |
| CN121358777A (zh) | 2023-07-27 | 2026-01-16 | 伊玛提克斯生物技术有限公司 | 抗mageb2的抗原结合蛋白 |
| WO2025021979A1 (en) | 2023-07-27 | 2025-01-30 | Immatics Biotechnologies Gmbh | Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20260098049A1 (en) | 2024-08-12 | 2026-04-09 | Gilead Sciences, Inc. | Kras modulating compounds |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596536B1 (en) | 1991-02-08 | 2003-07-22 | Aventis Pharma S.A. | Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses |
| WO2000020445A2 (en) | 1998-10-02 | 2000-04-13 | Ludwig Institute For Cancer Research | Tumor antigens and ctl clones isolated by a novel procedure |
| US6867283B2 (en) * | 2001-05-16 | 2005-03-15 | Technion Research & Development Foundation Ltd. | Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells |
| US7049413B2 (en) * | 2001-05-18 | 2006-05-23 | Ludwig Institute For Cancer Research | MAGE-A3 peptides presented by HLA class II molecules |
| IL160359A0 (en) | 2001-08-31 | 2004-07-25 | Avidex Ltd | Soluble t cell receptor |
| RU2355703C2 (ru) | 2002-10-09 | 2009-05-20 | Медиджен Лимитед | Одноцепочечные рекомбинантные т-клеточные рецепторы |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| JP5276846B2 (ja) | 2005-09-13 | 2013-08-28 | 国立大学法人三重大学 | Ｔ細胞レセプターをコードする核酸が挿入されてなるベクター及び該レセプターを発現する細胞 |
| ES2533228T3 (es) | 2009-06-09 | 2015-04-08 | Vaxon Biotech | Identificación, optimización y uso de epítopos compartidos de HLA-B*0702 para inmunoterapia |
| HRP20171164T1 (hr) | 2010-09-20 | 2017-10-20 | Biontech Cell & Gene Therapies Gmbh | Antigen-specifični t stanični receptori i t stanični epitopi |
| KR102499753B1 (ko) * | 2012-07-27 | 2023-02-16 | 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 | Ｔ 세포 수용체 조작 |
| CA3051222C (en) | 2013-06-10 | 2023-01-24 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for reducing immunosupression by tumor cells |
| BR112018070637A2 (pt) * | 2016-04-08 | 2019-02-05 | Adaptimmune Ltd | receptores de células t |
| KR20190059874A (ko) | 2016-04-08 | 2019-05-31 | 어댑티뮨 리미티드 | T 세포 수용체 |
| SMT202200306T1 (it) | 2016-04-08 | 2022-09-14 | Immunocore Ltd | Recettori di cellule t |
| DK3440106T3 (da) * | 2016-04-08 | 2021-10-04 | Adaptimmune Ltd | T-cellereceptorer |
-
2017
- 2017-04-10 KR KR1020187032021A patent/KR20190059874A/ko not_active Ceased
- 2017-04-10 CN CN202311577769.5A patent/CN117603339A/zh active Pending
- 2017-04-10 MX MX2018012265A patent/MX2018012265A/es unknown
- 2017-04-10 ES ES17723015T patent/ES2991142T3/es active Active
- 2017-04-10 SG SG11201808709VA patent/SG11201808709VA/en unknown
- 2017-04-10 WO PCT/EP2017/058576 patent/WO2017174822A1/en not_active Ceased
- 2017-04-10 AU AU2017248120A patent/AU2017248120B2/en not_active Ceased
- 2017-04-10 EP EP17723015.8A patent/EP3440102B1/en active Active
- 2017-04-10 CN CN201780031672.0A patent/CN110023330B/zh not_active Expired - Fee Related
- 2017-04-10 RU RU2018138836A patent/RU2018138836A/ru unknown
- 2017-04-10 JP JP2018552696A patent/JP7179616B2/ja active Active
- 2017-04-10 DK DK17723015.8T patent/DK3440102T3/da active
- 2017-04-10 CA CA3020530A patent/CA3020530A1/en active Pending
- 2017-04-10 BR BR112018070600A patent/BR112018070600A2/pt not_active IP Right Cessation
- 2017-04-10 EP EP24170484.0A patent/EP4389898A3/en not_active Withdrawn
-
2018
- 2018-10-04 IL IL262146A patent/IL262146A/en unknown
- 2018-10-08 US US16/154,161 patent/US20190135892A1/en not_active Abandoned
- 2018-10-15 ZA ZA2018/06865A patent/ZA201806865B/en unknown
-
2022
- 2022-01-12 US US17/574,152 patent/US12060404B2/en active Active
- 2022-07-04 JP JP2022107704A patent/JP7437452B2/ja active Active
- 2022-10-20 AU AU2022256181A patent/AU2022256181B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022153399A5 (https=) | ||
| JP2022122913A5 (https=) | ||
| JP2023081949A5 (https=) | ||
| JP2020127406A5 (https=) | ||
| CN109476724B (zh) | T细胞受体 | |
| CN110023330B (zh) | T细胞受体 | |
| JP2022554395A5 (https=) | ||
| CN102803487A (zh) | 癌抗原辅助肽 | |
| AR106920A1 (es) | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia linfocítica crónica (llc) y otros tipos de cáncer | |
| PE20190124A1 (es) | Linfocitos t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cancer | |
| JP2025105774A5 (https=) | ||
| AR088455A1 (es) | Anticuerpos que antagonizan cd40l | |
| AR105817A1 (es) | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer | |
| JP2013538555A5 (https=) | ||
| HRP20190472T4 (hr) | Klaudin-6 specifični imunoreceptori i t-stanični epitopi | |
| HRP20230512T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma jajnika i drugih karcinoma | |
| JP2023522799A5 (https=) | ||
| WO2014197821A1 (en) | Homeodomain fusion proteins and uses thereof | |
| JP2023524788A5 (https=) | ||
| PE20231506A1 (es) | Peptidos y combinaciones de peptidos para su uso en inmunoterapia contra una infeccion por sars-cov-2 (covid-19) | |
| WO2021078774A1 (en) | Specific binding molecules | |
| JP2021531834A5 (https=) | ||
| JP2023542900A5 (https=) | ||
| PE20211499A1 (es) | Peptidos restringidos por a 03 para el uso en la inmunoterapia contra el cancer y metodos relacionados | |
| JP2023528255A5 (https=) |